LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Kodu・Aktsiate loetelu・Nektar Therapeutics
Search

Nektar Therapeutics

Suletud

83.3 -2.05

Tugev "osta" hinnang

Hinna uuendus 7. mai 2026, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

81.86

Max

84.98

Põhinäitajad

By Trading Economics

Sissetulek

-557K

-36M

Müük

10M

22M

Aktsiakasum

-1.29

Kasumimarginaal

-165.447

Töötajad

63

EBITDA

10M

-19M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+72.72% upside

Turustatistika

By TradingEconomics

Turukapital

997M

2.9B

Eelmine avamishind

85.35

Eelmine sulgemishind

83.3

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

0.5949 / 0.7406 Toetus ja vastupanu

Nektar Therapeutics Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. mai 2026, 23:58 UTC

Tulu

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

DJ

Loe

7. mai 2026, 22:57 UTC

Tulu

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

DJ

Loe

7. mai 2026, 23:52 UTC

Tulu

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

DJ

Loe

7. mai 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

DJ

Loe

7. mai 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

DJ

Loe

7. mai 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

DJ

Loe

7. mai 2026, 23:11 UTC

Tulu

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

DJ

Loe

7. mai 2026, 23:06 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

DJ

Loe

7. mai 2026, 23:05 UTC

Tulu

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

DJ

Loe

7. mai 2026, 23:04 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

DJ

Loe

7. mai 2026, 23:03 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

DJ

Loe

7. mai 2026, 23:03 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

DJ

Loe

7. mai 2026, 23:02 UTC

Tulu

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

DJ

Loe

7. mai 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

DJ

Loe

7. mai 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

7. mai 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

DJ

Loe

7. mai 2026, 22:42 UTC

Tulu

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

DJ

Loe

7. mai 2026, 22:33 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

DJ

Loe

7. mai 2026, 22:32 UTC

Tulu

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

DJ

Loe

7. mai 2026, 22:31 UTC

Tulu

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

DJ

Loe

7. mai 2026, 22:31 UTC

Tulu

Macquarie: 68% of FY Income From International >MQG.AU

DJ

Loe

7. mai 2026, 22:30 UTC

Tulu

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

DJ

Loe

7. mai 2026, 22:30 UTC

Tulu

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

DJ

Loe

7. mai 2026, 22:29 UTC

Tulu

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

DJ

Loe

7. mai 2026, 22:28 UTC

Tulu

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

DJ

Loe

7. mai 2026, 22:28 UTC

Tulu

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

DJ

Loe

7. mai 2026, 22:27 UTC

Tulu

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

DJ

Loe

7. mai 2026, 22:27 UTC

Tulu

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

DJ

Loe

7. mai 2026, 22:26 UTC

Tulu

Macquarie to End Share Buyback Extended in November>MQG.AU

DJ

Loe

7. mai 2026, 22:25 UTC

Tulu

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Nektar Therapeutics Prognoos

Hinnasiht

By TipRanks

72.72% tõus

12 kuu keskmine prognoos

Keskmine 144 USD  72.72%

Kõrge 185 USD

Madal 95 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Nektar Therapeutics 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

7

Osta

1

Hoia

0

Müü

Põhineb 8 analüütiku instrumendi Nektar Therapeutics aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.5949 / 0.7406Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Strong Bearish Evidence

All events are bearish.

Pikk perspektiiv

Bearish Evidence

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

974.96

↓-1.19%

JNJ

Johnson and Johnson

222.47

↓-0.89%

ABBV

AbbVie Inc

202.58

↓-1.21%

UNH

UnitedHealth Group Inc

369.71

↑ +0.7%

AZN

AstraZeneca PLC

182.23

↓-1.36%
help-icon Live chat